Clinical Service Incorporating Mobile Technology on Weight Loss in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Translation From Research Trial
Endocrinology, Diabetes & Metabolism · 2024
DOI: 10.1002/edm2.485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2024. Verfasst von Siew Min Ang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dietetics, National University Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Weight Loss, Telemedicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The prevalence and healthcare cost of metabolic dysfunction–associated steatotic liver disease (MASLD) has increased alongside the epidemic surge in obesity and Type 2 diabetes. Weight loss through lifestyle modification remains the primary effective therapy for MASLD. Incorporation of mobile technology in lifestyle interventions has been previously found to be efficacious and cost‐effective in facilitating weight loss. However, there is a paucity of studies that have successfully translated lifestyle research into clinical service for weight loss to alleviate disease burden. Our study aimed to describe the process of translating a mobile technology–enabled trial into a tertiary hospital outpatient dietetics service for patients with MASLD.
Methods
The Iowa Model of Evidence‐Based Practice to Improve Quality Care was used as a framework for this paper to guide implementation at the organizational level.
Results
Regular engagement of key operational staff and the hospital management team facilitated open discussions of the challenges faced and enabled rapid implementation of strategies that contributed to the smooth piloting of the service. A service adoption rate of 81% was achieved. Preliminary outcome evaluation found that the percentage of patients achieving ≥ 5% weight loss from baseline at 6 months was comparable at 54% and 52% for the service and trial groups, respectively.
Conclusions
Evaluation of the implementation process found that a hybrid model of care (in‐person consultation supplemented with app coaching) preserved interpersonal connections while maximizing the convenience and scalability of mobile app–enabled service. Although high digital acceptance and adoption rates propelled by COVID‐19‐supported telehealth, it is prudent to assess patient's access to technology and digital literacy and offer resources to help them benefit from telehealth services.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dietetics, National University Hospital, Singapore, Singapore.
- Department of Medicine, National University Hospital, Singapore, Singapore.
- Biostatistics Unit, Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore.
- Susan Wakil School of Nursing and Midwifery, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Juliana Chen
Zitieren
APA
Ang, S. M., Lim, S. L., Dan, Y. Y., Chan, Y. H., Yap, Q. V., & Chen, J. (2024). Clinical Service Incorporating Mobile Technology on Weight Loss in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Translation From Research Trial. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.485
Vancouver
Ang SM, Lim SL, Dan YY, Chan YH, Yap QV, Chen J. Clinical Service Incorporating Mobile Technology on Weight Loss in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Translation From Research Trial. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.485
BibTeX
@article{Ang2024,
author = {Ang, Siew Min and Lim, Su Lin and Dan, Yock Young and Chan, Yiong Huak and Yap, Qai Ven and Chen, Juliana},
title = {Clinical Service Incorporating Mobile Technology on Weight Loss in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Translation From Research Trial},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
doi = {10.1002/edm2.485}
}
EUVIMED